Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v12-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2025-01-06 | 2024-08-07 |
| Drug Identification Number | 02520834 | 02520834 |
| Brand name | ZEPZELCA | ZEPZELCA |
| Common or Proper name | Lurbinectedin | Lurbinectedin |
| Company Name | JAZZ PHARMACEUTICALS IRELAND LIMITED | JAZZ PHARMACEUTICALS IRELAND LIMITED |
| Ingredients | LURBINECTEDIN | LURBINECTEDIN |
| Strength(s) | 4MG | 4MG |
| Dosage form(s) | POWDER | POWDER |
| Route of administration | INTRAVENOUS | INTRAVENOUS |
| Packaging size | Carton containing 1 vial | Carton containing 1 vial |
| ATC code | L01XX | L01XX |
| ATC description | ||
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2024-11-01 | 2025-01-01 |
| Actual start date | 2024-11-01 | |
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | This is a supply decision specific to Canada as a result of the reimbursement assessment by CADTH and INESSS. In 2023, both CADTH and INESSS issued a 'do not list' recommendation. With no available pathway in the near term for reimbursement, at this time, the company will not be able to continue maintaining supply of Zepzelca in Canada (beyond what is currently in country). | Since December 2021, following Health Canada marketing authorisation, patients have been receiving Zepzelca under a patient access programme. In 2023, both CADTH and INESSS issued a 'do not list' recommendation. |
| Health Canada comments |